Berlin - People with statutory health insurance will have to be prepared from April to having to pay an additional five to ten euros per prescription for prescription drugs that were previously free of copayment. The German Pharmacists' Association () has pointed this out.
According to the DAV, this could primarily affect strong pain relievers with the active ingredients fentanyl, morphine and oxycodone as well as substances often prescribed by doctors such as prednisolone or clopidogrel. In addition, fixed amount will be set for Infliximab for the first time on April 1st.
The reason is that the maximum reimbursement limits for 18 fixed amount groups has lowered. He expects annual savings of 105 million euros from this. If the pharmaceutical manufacturers do not lower their prices at the same time, according to the DAV, new co-payment obligation may arise.
"The ever lower prices mean that pharmaceutical manufacturers can no longer produce economically at fixed price," warned Hermann Kortland, Deputy General Manager of the Federal Association of Drug Manufacturers (). Therefore, the drugs would often have to be paid for or, in the worst case, would have to be withdrawn from the market and would no longer be available for patient care. Kortland called it “incomprehensible” that the statutory health insurance system continues to save by reducing fixed amounts despite record increase.